AIEgen‐Based Photothermal Nanoparticles With Dual Antibacterial and Anti‐Inflammatory Activities for Enhanced Healing of Infected Diabetic Wounds

Why It Matters

The technology tackles MDR infections in diabetic ulcers where antibiotics fail, while simultaneously promoting tissue regeneration, potentially lowering amputation rates and healthcare costs.

Key Takeaways

• NIR-activated AIEgen achieves high photothermal conversion
• Eradicates MRSA and CRPA in diabetic wound models
• Disrupts biofilms and reduces local inflammation
• Promotes M2 macrophage polarization and angiogenesis
• Enables faster healing of infected diabetic foot ulcers

Pulse Analysis

Diabetic foot ulcers (DFUs) represent a costly, chronic complication of diabetes, compounded by the rise of multidrug‑resistant (MDR) pathogens that resist conventional antibiotics. Traditional topical or systemic treatments often lack deep tissue penetration and cannot eradicate resilient biofilms, leading to prolonged infections and higher amputation risk. Photothermal therapy, which converts light energy into localized heat, has emerged as a promising alternative, yet many agents suffer from poor stability or toxicity. The newly reported aggregation‑induced emission luminogen (AIEgen) merges strong near‑infrared (NIR) absorption with exceptional photostability, offering a safe, deep‑penetrating platform tailored for DFU applications.

When exposed to NIR light, the AIEgen nanoparticles generate rapid hyperthermia that disrupts bacterial membranes and penetrates biofilm matrices, achieving broad‑spectrum bactericidal activity against clinical isolates such as MRSA and carbapenem‑resistant Pseudomonas aeruginosa. Beyond direct killing, the thermal stimulus modulates the wound microenvironment: it dampens pro‑inflammatory cytokines, rebalances macrophage phenotypes toward the reparative M2 state, and stimulates angiogenic signaling pathways. This dual antibacterial‑anti‑inflammatory action creates a conducive niche for tissue regeneration, addressing two critical bottlenecks in chronic wound healing.

Preclinical studies in a diabetic mouse model demonstrated that a single AIEgen‑NIR treatment accelerated wound closure by over 40% compared with controls, increased collagen deposition, and promoted robust neovascularization. Importantly, systemic toxicity remained negligible, underscoring the biocompatibility of the platform. As the global market for advanced wound care expands, this photothermal nanotechnology could redefine standard-of‑care protocols, offering clinicians a non‑antibiotic, minimally invasive tool to combat MDR infections while enhancing healing outcomes. Continued translational work and scalable manufacturing will be key to unlocking its commercial potential.